A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers

Next Previous
Trial Profile

A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Rifamycin (Primary) ; Ciprofloxacin
  • Indications Traveller's diarrhoea
  • Focus Registrational; Therapeutic Use
  • Acronyms ERASE
  • Sponsors Dr Falk Pharma

    • Most Recent Events

    • 26 May 2017 Status changed from active, no longer recruiting to completed.
    • 09 May 2017 Primary endpoint (Time to Last Unformed Stool (TLUS)) has been met, according to results presented at the Digestive Disease Week 2017.
    • 09 May 2017 Results presented at the Digestive Disease Week 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top